Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
The present invention relates in general to the field of modulators of the innate immune system, particularly to pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof, preferably suitable for local administration, such as, intravesical administration. In addition, the present invention concerns the use of imidazoquinolin(amines) and derivatives thereof for intravesical treatment of bladder diseases, such as, for example, bladder cancer and cystitis. The present invention furthermore comprises methods of treatment for these diseases as well as methods of administration of the inventive pharmaceutical compositions.
1. A method for treating superficial bladder cancer in a subject comprising: intravesically administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising lactic acid, a single poloxamer in an amount of about 11% (w/v) to about 18% (w/v), cyclodextrin and a compound having a structure of formula A:
or a pharmaceutically acceptable salt, tautomer or hydrate thereof.
2. The method of claim 1 , wherein the poloxamer is Poloxamer 407.
3. The method of claim 1 , wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD).
4. The method of claim 1 , wherein the compound is in an amount of about 0.1% (w/v) to about 1% (w/v).
5. The method of claim 1 , wherein the lactic acid is in a concentration of about 0.025 to about 0.2 M or in a concentration of about 0.075 to about 0.125 M.
6. The method of claim 1 , wherein the cyclodextrin of the pharmaceutical composition is in an amount of about 2% (w/v) to about 6% (w/v).
7. The method of claim 1 , wherein the poloxamer of the pharmaceutical composition is in an amount of about 12% (w/v) to about 17 25% (w/v).
8. The method of claim 7 , wherein the poloxamer of the pharmaceutical composition is in an amount of about 14% (w/v) to about 16.5% (w/v).
9. The method of claim 1 , wherein the poloxamer is Poloxamer 407 and the cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD).
10. The method of claim 9 , wherein the pharmaceutical composition comprises a compound having the structure of formula A in an amount of about 0.1% (w/v) to about 1% (w/v), lactic acid in a concentration of about 0.025 to about 0.2 M or in a concentration of about 0.075 to about 0.125 M, Poloxamer 407 in an amount of about 11% (w/v) to about 18% (w/v) and hydroxypropyl-β-cyclodextrin (HP-β-CD) in an amount of about 2% (w/v) to about 6% (w/v) and the pharmaceutical composition is aqueous.
11. The method of claim 1 , wherein the compound having the structure of formula A is in an amount of about 0.005% (w/v) to about 5% (w/v).
12. The method of claim 1 , wherein the cyclodextrin is selected from α-cyclodextrins, β-cyclodextrins, γ-cyclodextrins, δ-cyclodextrins, ε-cyclodextrins, and hydroxypropyl-β-cyclodextrin (HP-β-CD).
13. The method of claim 1 , wherein the cyclodextrin in an amount of about 0.1% (w/v) to about 30% (w/v).
14. The method of claim 1 , wherein the pharmaceutical composition is aqueous.
15. The method of claim 10 , wherein the Poloxamer 407 in an amount of about 15.5% (w/v) to about 16.5% (w/v).